On November 29, Annie and Ilan Ganot P’26, co-founders of Solid Biosciences, a Boston-based biotechnology company, gave an inspiring presentation to the CA community. They shared how they are developing treatments for Duchenne muscular dystrophy, a progressive and life-limiting muscle-wasting disease that afflicts approximately 10,000 boys in the United States alone, including their son. The Ganots shared how they leveraged their expertise, networks, and unrelenting drive as parents and professionals to push boundaries in science and technology to improve the lives of patients living with Duchenne.
Finepoint Capital LP acquired a new position in Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 218,562 shares of the company’s stock, valued at approximately $1,176,000. Solid Biosciences makes up approximately 0.4% of Finepoint Capital […]
Arcellx (NASDAQ:ACLX – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Risk and Volatility Arcellx has a beta of -0.33, indicating […]
Solid Biosciences (NASDAQ:SLDB – Get Rating) and Arcellx (NASDAQ:ACLX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Volatility and Risk Solid Biosciences has a beta of 1.47, indicating […]
Solid Biosciences (NASDAQ:SLDB – Get Rating) and Arcellx (NASDAQ:ACLX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Solid Biosciences has a beta of 1.47, […]